European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive…
High risk of financial vulnerability after diagnosis: The majority of people impacted by lung cancer experience higher costs and reduction in income Financial impact of lung…
This is an annual initiative led by lung cancer patient organisations, across Europe with the purpose of raising awareness relating to the main challenges faced…
Join us at our launch of the 8th LuCE report: “Financial impact on lung cancer: A European Perspective”
November 14th – 15th in Amsterdam We are delighted to announce that Lung Cancer Europe (LuCE) is participating in a two-day meeting at the European Medicines Agency…
We are very sad to share the heartbreaking news that Marjo Forsblom passed away on Sunday October 22nd 2023. Marjo was a beautiful shining light…
LuCE present at the ESMO Congress 2023 October 20th-24th in Madrid, Spain Our president Anne-Marie Baird had an active participation at the ESMO Congress as…
About the Organization Lungunion Austria The Lungunion Austria is a patient organization (NGO and self-aid organization) for people with airway diseases, aligned skin diseases, and…
During our Members Meeting 2023, 11 members presented their advocacy initiatives where they shared their goals, projects and accomplishments. With an overwhelming number of votes,…